1. Huizinga MM, Rothman RL. Addressing the diabetes pandemic: a comprehensive approach. Indian J Med Res 2006; 124: 481-4.
2. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379: 165-80.
3. Toto RD. Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens (Greenwich) 2004; 6: 2-7.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98: S1-S115.
5. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012.
6. Süleymanlar G, Utaş C, Arinsoy T, et al. A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study. Nephrol Dial Transplant 2011; 26: 1862-71.
7. Jitraknatee J, Ruengorn C, Nochaiwong S. Prevalence and risk factors of chronic kidney disease among type 2 diabetes patients: a cross-sectional study in primary care practice. Sci Rep 2020; 10: 6205.
8. Ghaderian SB, Hayati F, Shayanpour S, Beladi Mousavi SS. Diabetes and end-stage renal disease; a review article on new concepts. J Renal Inj Prev 2015; 4: 28-33.
9. Reikes ST. Trends in end-stage renal disease. Epidemiology, morbidity, and mortality. Postgrad Med 2000; 108.
10. Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc 2018; 117: 662-75.
11. Toth-Manikowski S, Atta MG. Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. J Diabetes Res 2015; 2015: 697010.
12. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17: 365-70.
13. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001; 24: 382-91.
14. Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 2011; 6: 1041-8.
15. Welsh KJ, Kirkman MS, Sacks DB. Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions. Diabetes Care 2016; 39: 1299-306.
16. Thulé PM, Umpierrez G. Sulfonylureas: a new look at old therapy. Curr Diab Rep 2014; 14: 473.
17. Costello RA, Nicolas S, Shivkumar A. Sulfonylureas. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 23, 2022.
18. TEMD Diabetes Mellitus and Its Complications Diagnosis, Treatment and Follow-up Guide-2020
19. Black C, Donnelly P , McIntyre L, Royle PL, Shepherd JP , Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; 2007: CD004654.
20. Flory J, Lipska K. Metformin in 2019. JAMA 2019; 321: 1926-7.
21. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-49.
22. Golay A. Metformin and body weight. Int J Obes (Lond) 2008; 32: 61-72.
23. Lv Z, Guo Y . Metformin and its benefits for various diseases. Front Endocrinol (Lausanne) 2020; 11: 191.
24. Zhang J, Huang L, Shi X, et al. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway. Aging (Albany NY) 2020; 12: 24270-87.
25. Corcoran C, Jacobs TF. Metformin. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 2, 2022.
26. Tomkin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin-B12 status of patients on long-term metformin therapy. Br Med J 1971; 2: 685-7.
27. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism 2016; 65: 20-9.
28. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333-45.
29. Singh G, Can AS, Correa R. Pioglitazone. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 17, 2022.
30. McIver LA, Tripp J. Acarbose. [Updated 2021 Aug 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https: //www.ncbi.nlm.nih.gov/books/NBK493214/
31. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007; 21: 517-33.
32. Clifton P. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Clin Ther 2014; 36: 2072-9.
33. Saisho Y. SGLT2 Inhibitors: the Star in the treatment of type 2 diabetes? Diseases 2020; 8: 14.
34. Çavuşoğlu Y, Altay H, Cahn A, et al. Sodium glucose co-transporter 2 inhibitors in heart failure therapy. Kalp yetersizliği tedavisinde sodyum glukoz ko-transporter 2 inhibitörleri. Turk Kardiyol Dern Ars 2020; 48: 330-54.